Eli Lilly and Novo Nordisk Raise Profit Forecasts Amid Weight Loss Drug Boom

Pharmaceutical giants Eli Lilly and Novo Nordisk have both increased their profit and revenue projections for the year due to surging demand for obesity and diabetes medications. Eli Lilly reported that second quarter revenue jumped 48 percent to 23 billion dollars, driven by strong sales of Mounjaro and Zepbound. The company now expects annual revenue to be between 85 billion and 87 billion dollars, which is an increase from its previous estimate of 82 billion to 85 billion dollars.

Novo Nordisk also raised its outlook, stating that growth for sales and adjusted operating profit is expected to be stable or decline by up to 6 percent, an improvement over its previous projection of a decline of up to 12 percent. The company recorded second quarter net sales of 78.5 billion Danish kroner and an adjusted operating profit of 33.4 billion Danish kroner.

Despite the positive forecasts, the stock prices of the two companies diverged. Eli Lilly shares rose more than 5 percent in pre market trading. In contrast, Novo Nordisk shares fell nearly 6 percent on Wednesday. Investors expressed concern over Novo Nordisk's heavy reliance on its GLP 1 products, such as Ozempic and Wegovy, which accounted for 93 percent of its revenue last quarter. For comparison, obesity and diabetes treatments represented approximately 65 percent of Eli Lilly's revenue.

Novo Nordisk CEO Mike Doustdar stated he was surprised by the market reaction, noting that the company's projections had improved significantly. He acknowledged the competition with Eli Lilly but emphasized a long history of mutual respect between the two firms. Novo Nordisk has faced recent challenges, including a cardiovascular drug that failed to reduce risks of heart attack and stroke in certain patients, and pressure to reduce prices in the United States.